Key Points
- Three US obesity-medicine specialists told a MedPage Today roundtable that two new obesity medicines will reach the market within six to seven months, with more arriving over the next three to five years.
- The pipeline is broadening beyond GLP-1 and GIP/GLP-1 drugs to triple agonists, amylin analogs and peripherally acting agents, shifting the clinical question from 'which drug' to 'which drug for which patient'.
- Amylin analogs promise a lower gastrointestinal side-effect burden but carry a fatigue signal, while triple agonists could push average total body weight loss toward 30% at the highest doses.
Inside the Next Wave of Obesity Drugs
Three leading US obesity-medicine specialists used a MedPage Today roundtable to sketch out what the next phase of obesity treatment will look like — and their message is that the field is about to get far more crowded and far more complicated. Moderator Robert Kushner, MD, of Northwestern University Feinberg School of Medicine, was joined by Deborah Horn, DO, of the University of Texas McGovern Medical School and Angela Fitch, MD, of the Boston-based practice knownwell, for the first of five episodes on GLP-1 therapies.
The clinical landscape is shifting from single GLP-1 receptor drugs and dual GIP/GLP-1 agents toward triple agonists, amylin analogs and other novel mechanisms. Horn said two new medicines should arrive within six to seven months, with at least one more likely before the end of the year, and a broader wave landing over the next three to five years. The highest dose of one upcoming triple agonist can produce average total body weight loss of about 30%, she said, while even its second dose can reach roughly 20% — raising the question of how much efficacy a given patient actually needs.
Amylin analogs drew particular attention. Horn described them as a hot topic that has been building for about a year, with weight-loss results that may approach current therapies and a side-effect profile that looks different: less gastrointestinal distress, which could appeal to patients who struggled with GLP-1 drugs, but a slightly stronger signal of fatigue that clinicians will have to learn to manage.
The panel also flagged a shift in where these drugs act. Most existing obesity medicines work centrally on appetite and satiety, but future agents are expected to target peripheral tissues, including muscle. Horn said she has already begun measuring patients' resting metabolic rates in anticipation of medicines that could address low metabolism directly — a capability that does not exist today.
At a Glance
| Event | MedPage Today expert roundtable First of five episodes on GLP-1 therapies and the future of obesity management. |
| Moderator | Robert Kushner, MD Professor emeritus, Northwestern University Feinberg School of Medicine, Chicago. |
| Panelist | Deborah Horn, DO University of Texas McGovern Medical School, Houston; focuses on the coming drug pipeline. |
| Panelist | Angela Fitch, MD knownwell, Boston; focuses on clinical adoption and technology support tools. |
| Key Drug Classes | Triple agonists, amylin analogs Emerging obesity treatments discussed as the next generation after GLP-1 and GIP/GLP-1 drugs. |
| Key Efficacy Figure | Up to 30% total body weight loss Average result cited for the highest dose of an unnamed triple agonist. |
| Key Timeline | Two new medicines in 6-7 months Panelists expect at least one additional approval before the end of the year. |
| Key Term | Precision medicine / phenotyping Matching a specific obesity drug to a patient's biology rather than prescribing by efficacy alone. |
What the GLP-1 Pipeline Means for Payers, Providers and Patients
From 'Which Drug' to 'Which Patient'
The most consequential idea in the roundtable is not any single molecule but the move toward precision prescribing. Horn framed the coming years as a shift from choosing a drug by efficacy alone to phenotyping — and eventually genotyping — the patient in front of you. That matters commercially because it changes what a successful obesity franchise looks like: a drug that wins on average weight loss may lose ground to a competitor that is safer or better matched to a defined subgroup, such as patients with liver disease. Fitch pointed to glucagon-containing agents as an example, noting they may target liver fat more aggressively in patients with MASLD or MASH.
Why Amylin Analogs Could Take Share
Amylin analogs are emerging as the most credible near-term challenger to GLP-1 dominance. Their appeal is not superior weight loss — Horn suggested results may be comparable to or below current tools — but tolerability. A lower gastrointestinal side-effect burden addresses one of the main reasons patients discontinue GLP-1 therapy, which is a real commercial problem for makers of incumbent drugs. The trade-off is a fatigue signal that clinicians will need to counsel patients on. For drugmakers, this is a reminder that in obesity care, tolerability and persistence can be as commercially decisive as efficacy.
Technology as the Bottleneck Breaker
Both panelists argued that clinical-decision-support tools embedded in electronic medical records, and patient-facing apps that answer questions about constipation or suggest protein-rich meals, will be essential to managing a larger drug menu. Fitch said her practice's app already handles such queries; Horn described a University of Texas tool that returned advice matching about 99% of what she would have told the patient herself. For context, this mirrors a broader trend in healthcare IT, where AI triage tools are being positioned less as a replacement for clinicians than as a way to absorb administrative load — and, in obesity care specifically, to keep patients on therapy long enough to see results.
Access Remains the Unresolved Question
Fitch closed by tying the pipeline's promise to coverage, saying she hopes for more expansive reimbursement so more patients can reach what she called life-changing care. The roundtable did not address pricing, insurer coverage criteria or the compounded-drug market — all of which will determine whether a broader drug menu translates into broader treatment. That gap is the main uncertainty hanging over the panel's otherwise optimistic outlook.
How Clinicians and Health Systems Should Prepare
The obesity drug market is about to fragment, and the winners will be decided by tolerability and patient matching, not raw weight-loss averages.
- Clinicians (0-6 months): Expect two new obesity medicines within six to seven months and at least one more before year-end. Pick one new agent, learn it thoroughly, and begin using it rather than waiting to master the entire pipeline.
- Clinicians (6-24 months): Start measuring resting metabolic rate now, as Horn has done, so that patients with genetically low metabolism or high metabolic adaptation can be identified when metabolism-targeting drugs arrive.
- Health systems: Prioritize clinical-decision-support tools inside the EMR and patient-facing apps that can handle routine questions — constipation management, meal composition — to absorb the workload of a larger drug menu.
- Payers and pharmacy directors: Prepare for formulary decisions that weigh amylin analogs' lower GI side-effect profile and fatigue signal against triple agonists' higher weight-loss ceiling, since step-therapy logic built around GLP-1s may not fit the new classes.
- Watch: the first triple-agonist approval and its label dose range; amylin-analog tolerability data on fatigue; and any movement on insurance coverage criteria, which Fitch identified as the gating factor for patient access.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Incumbent GLP-1 franchises face share erosion as amylin analogs with lower GI side effects and triple agonists with up to 30% weight loss enter the market within three to five years. |
| Competitive Risk | High | The roundtable describes a crowded pipeline — triple agonists, amylin analogs, muscle-targeting and peripherally acting agents — arriving in a compressed window of six months to five years. |
| Regulatory Risk | Low | The discussion covers clinical and pipeline matters; no specific regulatory action, filing or approval decision is named in the source. |
| Reputation Risk | Low | No company, brand or executive is named in connection with a safety issue or controversy in the roundtable. |
| Technology Disruption | High | AI-driven clinical-decision-support tools in EMRs and patient-facing apps are positioned as essential to managing a broader drug menu, with one tool reportedly matching clinician advice 99% of the time. |
| Commercial Opportunity | High | A larger, more differentiated drug menu plus precision prescribing creates room for new entrants to win share on tolerability and patient matching rather than raw efficacy alone. |
Comments 0